CD8A and neoplasm: However, the status of PD-L1 expression on tumor cells alone is not sufficient to identify patients who might respond to PD-1/PD-L1 blockade immunotherapy; mismatch repair and the presence of tumor-infiltrating lymphocytes including CD8+ T cell and Tregs in tumor samples could also influence the immune response (39, 40).